Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
Natama HM, Salkeld J, Somé A, Soremekun S, Diallo S, Traoré O, Rouamba T, Ouédraogo F, Ouédraogo E, Daboné KCS, Koné NA, Compaoré ZMJ, Kafando M, Bonko MDA, Konaté F, Sorgho H, Nielsen CM, Pipini D, Diouf A, King LDW, Shaligram U, Long CA, Cho JS, Lawrie AM, Skinner K, Roberts R, Miura K, Bradley J, Silk SE, Draper SJ, Tinto H, Minassian AM. Natama HM, et al. Among authors: shaligram u. Lancet Infect Dis. 2024 Dec 10:S1473-3099(24)00752-7. doi: 10.1016/S1473-3099(24)00752-7. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39672183 Free article.
A Combined LC-MS and Immunoassay Approach to Characterize Preservative-Induced Destabilization of Human Papillomavirus Virus-like Particles Adsorbed to an Aluminum-Salt Adjuvant.
Caringal RT, Hickey JM, Sharma N, Jerajani K, Bewaji O, Brendle S, Christensen N, Batwal S, Mahedvi M, Rao H, Dogar V, Chandrasekharan R, Shaligram U, Joshi SB, Volkin DB. Caringal RT, et al. Among authors: shaligram u. Vaccines (Basel). 2024 May 26;12(6):580. doi: 10.3390/vaccines12060580. Vaccines (Basel). 2024. PMID: 38932309 Free PMC article.
Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases.
Shengule S, Alai S, Bhandare S, Patil S, Gautam M, Mangaonkar B, Gupta S, Shaligram U, Gairola S. Shengule S, et al. Among authors: shaligram u. Vaccines (Basel). 2024 Apr 18;12(4):433. doi: 10.3390/vaccines12040433. Vaccines (Basel). 2024. PMID: 38675815 Free PMC article.
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, Garg BS, Gogtay NJ, Tambe M, Lalwani S, Singh K, Munshi R, Meshram S, Selvavinayagam TS, Pandey K, Bhimarasetty DM, Ramakrishnan SR, Bhamare C, Dharmadhikari A, Budhawant C, Bonhomme CJ, Thakar M, Kurle SN, Kelly EJ, Gautam M, Gupta N, Panda S, Bhargava B, Poonawalla CS, Shaligram U, Kapse D, Gunale B. Kulkarni PS, et al. Among authors: shaligram u. Hum Vaccin Immunother. 2024 Dec 31;20(1):2304974. doi: 10.1080/21645515.2024.2304974. Epub 2024 Mar 21. Hum Vaccin Immunother. 2024. PMID: 38512394 Free PMC article. Clinical Trial.
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS, Dicko A, Tinto H, Ouédraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S, Chemba M, Compaore YD, Issiaka D, Salou D, Some AM, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood BM, Ewer KJ, Bradley J, Kulkarni PS, Shaligram U, Hill AVS; R21/Matrix-M Phase 3 Trial Group. Datoo MS, et al. Among authors: shaligram u. Lancet. 2024 Feb 10;403(10426):533-544. doi: 10.1016/S0140-6736(23)02511-4. Epub 2024 Feb 1. Lancet. 2024. PMID: 38310910 Free article. Clinical Trial.
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, Joshi S, Pimple S, Kawade A, Balasubramani L, Thomas A, Suri V, Lalwani S, Uday R, Kamath V, Mandal R, Rajeswar A, Peedicayil A, Poli UR, Banerjee D, Sankaranarayanan R, Basu P, Muwonge R, Gairola S, Dogar V, Rao H, Shaligram U. Sharma H, et al. Among authors: shaligram u. Lancet Oncol. 2023 Dec;24(12):1321-1333. doi: 10.1016/S1470-2045(23)00480-1. Epub 2023 Nov 7. Lancet Oncol. 2023. PMID: 37949086 Clinical Trial.
Large-Scale Purification and Characterization of Recombinant Receptor-Binding Domain (RBD) of SARS-CoV-2 Spike Protein Expressed in Yeast.
Nagar G, Jain S, Rajurkar M, Lothe R, Rao H, Majumdar S, Gautam M, Rodriguez-Aponte SA, Crowell LE, Love JC, Dandekar P, Puranik A, Gairola S, Shaligram U, Jain R. Nagar G, et al. Among authors: shaligram u. Vaccines (Basel). 2023 Oct 16;11(10):1602. doi: 10.3390/vaccines11101602. Vaccines (Basel). 2023. PMID: 37897004 Free PMC article.
Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
Aydin I, May M, Pisano F, Mpofu-Maetzig N, Grode L, Parekh S, Pujari P, Shewale S, Desai S, Sharma H, Rao H, Gautam M, Gairola S, Shaligram U. Aydin I, et al. Among authors: shaligram u. Vaccine. 2023 Nov 2;41(46):6810-6819. doi: 10.1016/j.vaccine.2023.09.060. Epub 2023 Oct 10. Vaccine. 2023. PMID: 37827966 Clinical Trial.
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Kulkarni PS, Gunale B, Kohli S, Lalwani S, Tripathy S, Kar S, Raut S, Kulkarni P, Apte A, Bavdekar A, Bhalla HL, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Pryor M, Hamilton S, Thakar M, Sannidhi RS, Baranwal P, Bhamare C, Dharmadhikari A, Gupta M, Poonawalla CS, Shaligram U, Kapse D; COVOVAX-Booster Study Group. Kulkarni PS, et al. Among authors: shaligram u. Sci Rep. 2023 Oct 3;13(1):16579. doi: 10.1038/s41598-023-43578-w. Sci Rep. 2023. PMID: 37789040 Free PMC article. Clinical Trial.
The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.
Dzau V, Swaminathan S, Baker C, Bright RA, Castillo J, Chuan TC, Draghia-Akli R, Eardley-Patel R, Gao GF, Ishii K, Tebeje YK, Lambe T, Machingaidze S, Røttingen JA, Shaligram U, Simão M, Swarup R, Toussaint JF, Wairagkar NS. Dzau V, et al. Among authors: shaligram u. Lancet. 2023 Oct 28;402(10412):1507-1510. doi: 10.1016/S0140-6736(23)01775-0. Epub 2023 Sep 6. Lancet. 2023. PMID: 37683681 No abstract available.
45 results